January 18, 2016

First Stroke Patient Treated With Rapid Medical's Tigertriever

January 19, 2016—Rapid Medical, an Israel-based developer of neurovascular interventional devices, announced that the first patient has been treated with the company’s Tigertriever revascularization device, which has received European CE Mark approval. Rapid Medical plans to launch Tigertriever in Europe during the second quarter of 2016.

According to the company, the Tigertriever is a fully visible, controllable stentriever that can be adjusted by the physician to fit the dimensions of blocked blood vessels that cause acute ischemic stroke. The device’s controllable and visible braided stent design provides both excellent continuous adjustability and high radial force, stated the company.

In Rapid Medical’s announcement, Prof. René Chapot, MD, commented, “I am very pleased with the results and performance of the device. The Tigertriever’s unique braiding and adjustability allowed me to safely secure the blood clot during its retrieval and achieve complete recanalization in one attempt. The Tigertriever has vast clinical potential and I am very happy to be the first physician using this breakthrough device.” Prof. Chapot is Head of the Neuroradiology Department at Alfried Krupp Hospital in Essen, Germany.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

January 18, 2016

First Stroke Patient Treated With Rapid Medical's Tigertriever

Current Issue

Keep In Touch